Diasome Pharmaceuticals

Diasome Pharmaceuticals is a clinical-stage biotech leveraging its HDV™ platform to create liver-targeted therapies for metabolic diseases. Its core technology uses a lipid nanoparticle (bicelle) with a biotin tag to selectively deliver drug actives to hepatocytes, aiming to enhance efficacy and reduce side effects by restoring natural physiological pathways. The most advanced program, OPTI-2 (HDV-Rapid Acting Insulin), is in Phase 2b for Type 1 Diabetes, with preclinical programs in GLP-1 and serotonin-based therapies. As a private company, Diasome is positioned to address significant unmet needs in the large and growing diabetes and obesity markets.

Hepatocyte Directed Vesicle (HDV™): A lipid nanoparticle (bicelle) drug delivery platform with a biotin tag that targets hepatocytes in the liver's portal-hepatic region. It is designed to bind and deliver peptides, proteins, and hormones directly to the liver to enhance efficacy and reduce peripheral side effects.

Diasome competes in the crowded metabolic disease space dominated by large-cap biopharma (e.g., Novo Nordisk, Eli Lilly). Its differentiation is not the drug active itself, but its targeted delivery system. It must compete against next-generation standalone insulins and GLP-1s, as well as other drug delivery and liver-targeting technologies from other biotechs.